See every side of every news story

Browser Extension

Thursday, April 3, 2025

US Edition

Subscribe Login

Israel-Hamas Conflict

Natural Disasters

CureVac image

News from CureVac

News Home Page Local News Blindspot Feed International Covid-19

International North America South America Europe Asia Australia Africa

Trending Internationally Tariffs Donald Trump Natural Disasters Trade War Nintendo

Trending in U.S.Israel-Hamas Conflict Tariffs Baseball Natural Disasters Donald Trump

Trending in U.K.Israel-Hamas Conflict UK Economy Premier League Manchester United Soccer

Trending Topics

Tariffs Donald Trump Natural Disasters Trade War Israel-Hamas Conflict

CompanyAbout History Mission Blog Testimonials Group Subscriptions Subscribe Gift Free Trial Careers Affiliates

HelpHelp Center FAQ Contact Us For Educators/Libraries Media Bias Ratings Ownership and Factuality Ratings Referral Code News Sources Topics

ToolsApp Browser Extension Daily Newsletter Blindspot Report Newsletter Burst Your Bubble Newsletter Timelines

Gift Privacy Policy Manage Cookies Terms and Conditions

© 2025 Snapwise Inc

Search Blindspot Local

Top CureVac News

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - CureVac (NASDAQ:CVAC)

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - CureVac (NASDAQ:CVAC)

100% Center coverage: 1 sources

CureVac N.V. (NASDAQ:CVAC) on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac’s European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection. The opposition division largely dismissed the opposition originally filed by BioNTech SE (NASDAQ:BNTX) in April 2023, challenging the patent’s validity and maintaining the patent in amended form. Also Read: Deadly Bird Flu Strain Detected In Neva…See the Story

News from CureVac

Stay current with all the latest and breaking news from CureVac. Compare headlines and media bias behind news outlets on stories breaking today.

We’ve aggregated 2 of CureVac’s headlines and news stories over the past 3 months.

We’ve assigned a media bias rating of to CureVac. You can read more about our methodology here.

CureVac’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Stay current with all the latest and breaking news from CureVac. Compare headlines and media bias behind news outlets on stories breaking today. We’ve aggregated 2 of CureVac’s headlines and news stories over the past 3 months.

We’ve assigned a media bias rating of to CureVac. You can read more about our methodology here. CureVac’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about CureVac

Where is CureVac located?CureVac's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

You've scrolled to the bottom of the feed, there are no more stories.